Standout Papers
Citation Impact
Citing Papers
Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro
2006 StandoutNobel
Neutralizing antibody response during acute and chronic hepatitis C virus infection
2004 StandoutNobel
Complete Replication of Hepatitis C Virus in Cell Culture
2005 StandoutScienceNobel
Evidence for a functional RNA element in the hepatitis C virus core gene
2007 StandoutNobel
Mouse models of acute and chronic hepacivirus infection
2017 StandoutScienceNobel
Ultrastructural organisation of HCV from the bloodstream of infected patients revealed by electron microscopy after specific immunocapture
2016
Current progress in development of hepatitis C virus vaccines
2013
To Interfere and to Anti-interfere: The Interplay Between Hepatitis C Virus and Interferon
2002
Cellular Binding of Hepatitis C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate
2003
Discovery and functional interrogation of SARS-CoV-2 RNA-host protein interactions
2021 StandoutNobel
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Specific Cleavage of Hepatitis C Virus RNA Genome by Human RNase P
2002
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2018 Standout
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Increased Risk of Tumor Seeding After Percutaneous Radiofrequency Ablation for Single Hepatocellular Carcinoma
2001
Hepatitis C Virus in Alcoholic Patients with and without Clinically Apparent Liver Disease
1995
How chemokines organize the tumour microenvironment
2023
Assembly of infectious hepatitis C virus particles
2010
Hepatocellular carcinoma
2003 Standout
Treatment predictors of a sustained virologic response in hepatitis B and C
2008
SEC14L2 enables pan-genotype HCV replication in cell culture
2015 StandoutNatureNobel
Primary liver cancer: Worldwide incidence and trends
2004 Standout
Characteristics of hepatocellular carcinoma in Italy
1998
Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury
2011
Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era
2008
Completion of the entire hepatitis C virus life cycle in genetically humanized mice
2013 StandoutNatureNobel
Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes
2011
Evolution of Treatment-Emergent Resistant Variants in Telaprevir Phase 3 Clinical Trials
2013
Hepatic macrophage migration and differentiation critical for liver fibrosis is mediated by the chemokine receptor C-C motif chemokine receptor 8 in mice
2011
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir
2011
Molecular Determinants and Dynamics of Hepatitis C Virus Secretion
2012
Cirrhosis and Hepatocellular Carcinoma in HIV-Infected Veterans With and Without the Hepatitis C Virus
2004
Treatment triumphs
2014 StandoutNatureNobel
Turning Hepatitis C into a Real Virus
2010 StandoutNobel
Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
2007
Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’
2014
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
2013
Unravelling hepatitis C virus replication from genome to function
2005 StandoutNatureNobel
Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection
1998
Cell Entry of Hepatitis C Virus Requires a Set of Co-receptors That Include the CD81 Tetraspanin and the SR-B1 Scavenger Receptor
2003
Chronic Hepatitis C in Alcoholic Patients: Prevalence, Genotypes, and Correlation to Liver Disease
1995
High Density Lipoproteins Facilitate Hepatitis C Virus Entry through the Scavenger Receptor Class B Type I
2005
Resistance Analysis of Hepatitis C Virus Genotype 1 Prior Treatment Null Responders Receiving Daclatasvir And Asunaprevir
2013
Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus?
2012
Host neutralizing responses and pathogenesis of hepatitis C virus infection†
2008
Interferon sensitivity‐determining region of nonstructural region 5A of hepatitis C virus genotype 1b correlates with serum alanine aminotransferase levels in chronic infection
2005
Characterization of humoral and cell-mediated immune responses directed against hepatitis C virus F protein in subjects co-infected with hepatitis C virus and HIV-1
2005
Incidence and Cofactors of Hepatitis C Virus-related Hepatocellular Carcinoma: A Prospective Study of 12,008 Men in Taiwan
2003
Lethal Mutagenesis of Hepatitis C Virus Induced by Favipiravir
2016 StandoutNobel
Drug-Induced Hepatotoxicity
2003 Standout
Macrophages: Master Regulators of Inflammation and Fibrosis
2010 Standout
Morphologic Observations in Iron Overload: An Update
1994
Hepatocellular carcinoma
2012 Standout
Delayed Induction, Not Impaired Recruitment, of Specific CD8+ T Cells Causes the Late Onset of Acute Hepatitis C
2011 StandoutNobel
Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease
2004
Hepatitis C virus entry: Molecular biology and clinical implications
2006
Hepatocellular carcinoma in HIV-infected patients
2004
Cell entry of hepatitis C virus
2006
Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice
2014
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
2011
HIV coinfection shortens the survival of patients with hepatitis C virus‐related decompensated cirrhosis†
2005
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
1998
The role of resistance in HCV treatment
2012
Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
2012
The major form of hepatitis C virus alternate reading frame protein is suppressed by core protein expression
2008
Diagnosis, management, and treatment of hepatitis C: An update # † ‡
2008 Standout
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
2011
Development of Specific Antibodies to an ARF Protein in Treated Patients with Chronic HCV Infection
2007
RNA Interference and Single Particle Tracking Analysis of Hepatitis C Virus Endocytosis
2009
Mutations in nonstructural protein 5A gene and response to interferon in hepatitis C virus genotype 2 infection
1999
Management of Hepatocellular Carcinoma *
2005 Standout
Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Chapter 2 Cutting the Gordian Knot-Development and Biological Relevance of Hepatitis C Virus Cell Culture Systems
2008
Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis
1996
Treating viral hepatitis C: efficacy, side effects, and complications
2006
Macrophages in Tissue Repair, Regeneration, and Fibrosis
2016 Standout
High Density Lipoprotein Inhibits Hepatitis C Virus-neutralizing Antibodies by Stimulating Cell Entry via Activation of the Scavenger Receptor BI
2006
Hepatitis C virus and hepatocellualr carcinoma
1994
HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects
2004
HCV transmission in industrialized countries and resource-constrained areas
2013
Antiviral strategies in hepatitis C virus infection
2012
Biochemical and Morphological Properties of Hepatitis C Virus Particles and Determination of Their Lipidome
2010
Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
1999
Infection of peripheral mononuclear blood cells by hepatitis C virus
1992
Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection
2010
Protease Inhibitor–Resistant Hepatitis C Virus Mutants With Reduced Fitness From Impaired Production of Infectious Virus
2010
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development
2014
Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: Amino acid substitutions in the core region and low-density lipoprotein cholesterol levels
2006
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells
2013
Prospective Analysis of Risk Factors for Hepatocellular Carcinoma in Patients With Liver Cirrhosis
2003
Human occludin is a hepatitis C virus entry factor required for infection of mouse cells
2009 StandoutNatureNobel
Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells
2006 StandoutNobel
Hepatitis C virus: How genetic variability affects pathobiology of disease
2011
Adaptation of Hepatitis C Virus to Mouse CD81 Permits Infection of Mouse Cells in the Absence of Human Entry Factors
2010
NONO Detects the Nuclear HIV Capsid to Promote cGAS-Mediated Innate Immune Activation
2018
Progress towards elimination goals for viral hepatitis
2020
Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry
2007 StandoutNatureNobel
A diverse range of gene products are effectors of the type I interferon antiviral response
2011 StandoutNatureNobel
Hepatitis C virus and interferon resistance
2000
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation – A target for novel cancer therapy
2017
Genome-Scale Identification of SARS-CoV-2 and Pan-coronavirus Host Factor Networks
2020 StandoutNobel
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
2014
Mechanisms and significance of liver steatosis in hepatitis C virus infection
2006
Interaction of hepatitis C virus F protein with prefoldin 2 perturbs tubulin cytoskeleton organization
2006
Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection
2001
Hepatitis C virus ARFP/F protein interacts with cellular MM-1 protein and enhances the gene trans-activation activity of c-Myc
2008
Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis
1998
Genomic Analysis Reveals a Potential Role for Cell Cycle Perturbation in HCV-Mediated Apoptosis of Cultured Hepatocytes
2009 StandoutNobel
Structural biology of hepatitis C virus
2004
Bridging In Vitro and In Vivo Metabolism and Transport of Faldaprevir in Human Using a Novel Cocultured Human Hepatocyte System, HepatoPac
2013
Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide
1996 StandoutNobel
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
2014 Standout
Long-term response to interferon alpha is unrelated to“interferon sensitivity determining region” variability in patients with chronic hepatitis C virus-1b infection
1999
Hepatitis C virus entry into hepatocytes: Molecular mechanisms and targets for antiviral therapies
2010
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
2013 StandoutNobel
Micropatterned coculture of primary human hepatocytes and supportive cells for the study of hepatotropic pathogens
2015 StandoutNobel
A genetically humanized mouse model for hepatitis C virus infection
2011 StandoutNatureNobel
Sofosbuvir: A Review of its Use in Patients with Chronic Hepatitis C
2014
Hepatitis C Virus F Protein Up-Regulates c-myc and Down-Regulates p53 in Human Hepatoma HepG<sub>2</sub> Cells
2007
Novel Insights into Hepatitis C Virus Replication and Persistence
2004
Chronic hepatitis C virus (HCV) disease burden and cost in the United States
2012
Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
2014
Changes in sequences of core region, interferon sensitivity‐determining region and interferon and ribavirin resistance‐determining region of hepatitis C virus genotype 1 during interferon‐alpha and ribavirin therapy, and efficacy of retreatment
2012
What Are the Promising New Therapies in the Field of Chronic Hepatitis C After the First-Generation Direct-Acting Antivirals?
2012
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
2011 Standout
CXCR3 ligands in disease and therapy
2014
Functional hepatitis C virus envelope glycoproteins
2004
Liver transplantation for small hepatocellular carcinoma: The tumor-node-metastasis classification does not have prognostic power
1998
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study
2015
Percutaneous radiofrequency ablation for hepatocellular carcinoma
2005
TMEM41B Is a Pan-flavivirus Host Factor
2020 StandoutNobel
HCV and the hepatic lipid pathway as a potential treatment target
2011
Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy
2010
Hepatitis C Virus RNA Functionally Sequesters miR-122
2015 StandoutNobel
An in vitro model of hepatitis C virion production
2005
Genomic analysis of the host response to hepatitis C virus infection
2002
Transcriptional slippage prompts recoding in alternate reading frames in the hepatitis C virus (HCV) core sequence from strain HCV-1
2008
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles
2003 StandoutNobel
Cellular Determinants of Hepatitis C Virus Assembly, Maturation, Degradation, and Secretion
2007
Structure and Function of the Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets
2016 StandoutNobel
Hepatitis C Virus Envelope Glycoprotein E1 Forms Trimers at the Surface of the Virion
2015
Role of the Hepatitis C Virus Core+1 Open Reading Frame and Corecis-Acting RNA Elements in Viral RNA Translation and Replication
2008
Binding of Hepatitis C Virus to CD81
1998 StandoutScienceNobel
Regulation of Hepatitis C Virus Translation and Infectious Virus Production by the MicroRNA miR-122
2010
Internal Initiation Stimulates Production of p8 Minicore, a Member of a Newly Discovered Family of Hepatitis C Virus Core Protein Isoforms
2009 StandoutNobel
Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes
2003
Cooperativity in Virus Neutralization by Human Monoclonal Antibodies to Two Adjacent Regions Located at the Amino Terminus of Hepatitis C Virus E2 Glycoprotein
2012
Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients
2013
Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity
2007
Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis
2012
Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus
2012 StandoutNobel
Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope Glycoprotein
2005
High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein
2007 StandoutNobel
Initiation of Hepatitis C Virus Infection Is Dependent on Cholesterol and Cooperativity between CD81 and Scavenger Receptor B Type I
2006
Development of an Intergenotypic Hepatitis C Virus (HCV) Cell Culture Method To Assess Antiviral Susceptibilities and Resistance Development of HCV NS3 Protease Genes from HCV Genotypes 1 to 6
2010
Establishment of B-Cell Lymphoma Cell Lines Persistently Infected with Hepatitis C Virus In Vivo and In Vitro: the Apoptotic Effects of Virus Infection
2003
Statistical analysis of combined substitutions in nonstructural 5A region of hepatitis C virus and interferon response
2000
Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus
2017 StandoutNobel
Hepatitis C Virus Evasion Mechanisms from Neutralizing Antibodies
2011
Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN ‐free treatment and future perspectives
2016
Studying Hepatitis C Virus: Making the Best of a Bad Virus
2007 StandoutNobel
Hepatitis C virus entry: potential receptors and their biological functions
2006
Interferon Resistance of Hepatitis C Virus Genotype 1b: Relationship to Nonstructural 5A Gene Quasispecies Mutations
1998
Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission
2010
Association between Hepatitis C Virus and Very-Low-Density Lipoprotein (VLDL)/LDL Analyzed in Iodixanol Density Gradients
2006
Incorporation of Hepatitis C Virus E1 and E2 Glycoproteins: The Keystones on a Peculiar Virion
2014
Fast Hepatitis C Virus RNA Elimination and NS5A Redistribution by NS5A Inhibitors Studied by a Multiplex Assay Approach
2015 StandoutNobel
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Cellular cofactors affecting hepatitis C virus infection and replication
2007 StandoutNobel
Viral Determinants of Resistance to Treatment in Patients with Hepatitis C
2007
On the History of Hepatitis C Virus Cell Culture Systems
2013
In Vivo Tropism of Hepatitis C Virus Genomic Sequences in Hematopoietic Cells: Influence of Viral Load, Viral Genotype, and Cell Phenotype
1998
Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs
2002 StandoutNobel
Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo
2004
Neutralizing Antibody Response to Hepatitis C Virus
2011
The interaction of natural hepatitis C virus with human scavenger receptor SR‐BI/Cla1 is mediated by ApoB‐containing lipoproteins
2006
Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine
2018 StandoutNobel
A mouse model for beta 0-thalassemia.
1995 StandoutNobel
Human Apolipoprotein E Is Required for Infectivity and Production of Hepatitis C Virus in Cell Culture
2007
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Expression of the alternative reading frame protein of Hepatitis C virus induces cytokines involved in hepatic injuries
2007
Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes
2010
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
2003 StandoutNobel
Mutations in Hepatitis C Virus E2 Located outside the CD81 Binding Sites Lead to Escape from Broadly Neutralizing Antibodies but Compromise Virus Infectivity
2009 StandoutNobel
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins
2007
Hepatitis C Virus Nonstructural 5A Protein Induces Interleukin-8, Leading to Partial Inhibition of the Interferon-Induced Antiviral Response
2001
Influence of the genetic heterogeneity of the ISDR and PePHD regions of hepatitis C virus on the response to interferon therapy in chronic hepatitis C
2001
Characterization of Hepatitis C Virus Interaction with Heparan Sulfate Proteoglycans
2015
Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies
2008
Prospective Characterization of Full-Length Hepatitis C Virus NS5A Quasispecies during Induction and Combination Antiviral Therapy
2000
Ultrastructural and Biophysical Characterization of Hepatitis C Virus Particles Produced in Cell Culture
2010
Mutations in the non-structural protein 5A gene in patients with chronic hepatitis C virus 1b infection during repeated interferon treatment
2000
New therapeutic strategies in HCV: second‐generation protease inhibitors
2013
Different Requirements for Scavenger Receptor Class B Type I in Hepatitis C Virus Cell-Free versus Cell-to-Cell Transmission
2013 StandoutNobel
Differential Biophysical Properties of Infectious Intracellular and Secreted Hepatitis C Virus Particles
2006
Apolipoprotein E but Not B Is Required for the Formation of Infectious Hepatitis C Virus Particles
2009
Hypervariable Region 1 Differentially Impacts Viability of Hepatitis C Virus Strains of Genotypes 1 to 6 and Impairs Virus Neutralization
2010
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
2014
Structure of the catalytic domain of the hepatitis C virus NS2-3 protease
2006 StandoutNatureNobel
Works of Stanislas Pol being referenced
Inhibition of DPP 4 activity in humans establishes its in vivo role in CXCL 10 post‐translational modification: prospective placebo‐controlled clinical studies
2016
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection
2006
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
2013
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
2010
Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy
2005
Hepatitis C and human immune deficiency coinfection at the era of highly active antiretroviral therapy
2002
Influence of HFE gene polymorphism on the progression and treatment of chronic hepatitis C
2004
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
2015
Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease
1991
Applying a system approach to forecast the total hepatitis C virus‐infected population size: model validation using US data
2011
Histopathologic Efficacy of Ribavirin Monotherapy in Kidney Allograft Recipients with Chronic Hepatitis C
2004
Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth
2019
Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C
1997
Risk Factors for Hepatitis C Virus Transmission to Health Care Workers after Occupational Exposure: A European Case-Control Study
2005
Spontaneous and iatrogenic spreading of liver-derived cells into peripheral blood of patients with primary liver cancer
1997
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
2015
Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
2013
Serum hepatitis C virus RNA and hepatitis B virus DNA in non-A, non-B post-transfusional and sporadic chronic hepatitis
1992
Reciprocal Interactions Between Human Immunodeficiency Virus and Hepatitis C Virus Infections
1996
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa
1997
Dual Role of CCR2 in the Constitution and the Resolution of Liver Fibrosis in Mice
2009
Response to pegylated interferon alfa‐2a and ribavirin in chronic hepatitis C genotype 4
2009
Efficient replication of primary or culture hepatitis C virus isolates in human liver slices: A relevant ex vivo model of liver infection
2012
Side effects of interferon-α in treating hepatitis C virus infection
2001
Efficacy of the Protease Inhibitor BI 201335, Polymerase Inhibitor BI 207127, and Ribavirin in Patients With Chronic HCV Infection
2011
Rapid and early virological response to chronic hepatitis C treatment with IFN α2b or PEG-IFN α2b plus ribavirin in HIV/HCV co-infected patients
2007
Liver Resection and Needle Liver Biopsy Cause Hematogenous Dissemination of Liver Cells
1999
Persistent Hepatitis B Virus Infection in Subjects Without Hepatitis B Surface Antigen: Clinically Significant or Purely “Occult”?
2001
Hepatitis C viremia and anti-HCV antibodies in alcoholics
1992
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection
2009
Antigenic relevance of F protein in chronic hepatitis C virus infection
2004
Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study)
2003
Treatment of hepatitis C virus genotype 3‐infection
2013
66 SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R
2011
Antigenic relevance of F protein in chronic hepatitis C virus infection
2004
13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY
2011
1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS
2012
5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN
2011
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies
2015
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV
2010
Impaired expression of the peroxisome proliferator–activated receptor alpha during hepatitis C virus infection
2005
1195 BMS-650032, AN NS3 INHIBITOR, IN COMBINATION WITH PEGINTERFERON ALPHA-2A AND RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
2011
Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles
2002
Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization
1994
484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN
2011
P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL
2014
Safety, pharmacokinetics and antiviral effect of BILB 1941, a novel hepatitis C virus RNA polymerase inhibitor, after 5 days oral treatment
2009